Theriva Biologics Stock Today

TOVX Stock  USD 1.28  0.02  1.59%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 81

 
High
 
Low
Very High
Theriva Biologics is trading at 1.28 as of the 24th of November 2024; that is 1.59% up since the beginning of the trading day. The stock's open price was 1.26. Theriva Biologics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Theriva Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of December 2022 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
18th of December 2006
Category
Healthcare
Classification
Health Care
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 2.78 M outstanding shares of which 90.95 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. More on Theriva Biologics

Moving together with Theriva Stock

  0.75VALN Valneva SE ADRPairCorr
  0.63JNJ Johnson Johnson Sell-off TrendPairCorr

Moving against Theriva Stock

  0.8KZR Kezar Life SciencesPairCorr
  0.57MLYS Mineralys Therapeutics,PairCorr

Theriva Stock Highlights

Thematic Ideas
(View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Management, Biotech, Computers, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.730.69
Notably Up
Slightly volatile
Gross Profit Margin0.630.77
Significantly Down
Slightly volatile
Total Current Liabilities4.2 M6.7 M
Way Down
Pretty Stable
Non Current Liabilities Total9.2 M8.8 M
Sufficiently Up
Slightly volatile
Total Assets58 M55.2 M
Sufficiently Up
Slightly volatile
Total Current Assets14.4 M27.4 M
Way Down
Slightly volatile
Theriva Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theriva Biologics' financial leverage. It provides some insight into what part of Theriva Biologics' total assets is financed by creditors.
Liquidity
Theriva Biologics currently holds 2.15 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Theriva Biologics has a current ratio of 4.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Theriva Biologics' use of debt, we should always consider it together with its cash and equity.

Total Cash From Financing Activities

593,750
Theriva Biologics (TOVX) is traded on NYSE MKT Exchange in USA. It is located in 9605 Medical Center Drive, Rockville, MD, United States, 20850 and employs 22 people. Theriva Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.56 M. Theriva Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.78 M outstanding shares of which 90.95 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Theriva Biologics Probability Of Bankruptcy
Ownership Allocation
Theriva Biologics has 10.48 % of its outstanding shares held by insiders and 21.2 % owned by institutional holders.
Check Theriva Ownership Details

Theriva Biologics Historical Income Statement

At this time, Theriva Biologics' Cost Of Revenue is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 1.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 101.5 K in 2024. View More Fundamentals

Theriva Stock Against Markets

Theriva Biologics Corporate Management

Steven CPACFO, CEOProfile
Vincent PerroneDirector CommunicationProfile
Frank TufaroChief OfficerProfile
Vince WacherHead DevelopmentProfile
Lara GuzmanDirector OperationsProfile
Ramon AlemanySenior BoardProfile
Michael MDSenior DevelopmentProfile

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.